Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA7 | P43166 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31700926 | 1.00 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10487721 | 0.88 | ESR1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22468902 | 0.87 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL670944 | 0.86 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30349688 | 0.86 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6646079 | 0.85 | ESR1 (0.69) | ESR1LMNACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL277473 | 0.84 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2390790 | 0.84 | CA12 (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10487727 | 0.84 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19752389 | 0.83 | CHRNA1 (0.48) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109651146-A | A kind of preparation method and application of 3- methyl -4- formaldoxime yl benzoic acid ethyl ester | 荆楚理工学院 | 2019-04-19 | — | — | CN | claimed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20240415830-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO LLC (US) | 2024-12-19 | — | — | US | disclosed |
| CN-118930532-A | Preparation method of kidney disease treatment medicine | 北京康立生医药技术开发有限公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-4393920-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-11944619-B2 | Phenylalanine small organic compounds to directly modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3337497-B1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023048034-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND HAVING ETHYNYL GROUP | 東レ・ファインケミカル株式会社 | 2023-03-30 | — | — | WO | disclosed |
| WO-2023025277-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
| US-20210236481-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2021-08-05 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001044239-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-5516777-A | PROSTATE CANCER THERAPY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-14 | — | — | US | disclosed |
| US-5409928-A | Prostate diseases, alopecia | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-04-25 | — | — | US | disclosed |
| EP-0594149-A2 | Condensed pyrazole derivatives, method of manufacturing the same, and androgen inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-04-27 | — | — | EP | disclosed |
| EP-0206635-B1 | PREPARATION OF 3-AMINO-4-HYDROXYBENZOIC ACIDS | THE DOW CHEMICAL COMPANY (US) | 1989-11-15 | — | — | EP | disclosed |
| US-4835306-A | Preparation of 3-amino-4-hydroxybenzoic acids | THE DOW CHEMICAL COMPANY (US) | 1989-05-30 | — | — | US | disclosed |
| EP-0206635-A1 | Preparation of 3-amino-4-hydroxybenzoic acids | THE DOW CHEMICAL COMPANY (US) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | CA12 4403/4885CA1 1805/4885CA2 3763/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | CA12 4699/4885CA1 2570/4885CA2 4154/4885 |
| US-11944619-B2 | Phenylalanine small organic compounds to directly modulate PCSK9 protein activity | PCSK9, LDLR, APOL1 | CA12 4494/4885CA1 4784/4885CA2 4608/4885 |
| US-20210236481-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PCSK9, LDLR, APOB | CA12 4308/4885CA1 4712/4885CA2 4645/4885 |
| US-20250320205-A1 | STAT6 DEGRADERS | STAT6, STAT1, STAT5B | CA12 3120/4885CA1 4613/4885CA2 2130/4885 |
| US-20240415830-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PCSK9, LDLR, APOB | CA12 4308/4885CA1 4712/4885CA2 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.